Interact Bio applies antibody discovery and engineering to develop therapeutics targeting vascular biology and related diseases. Leveraging a team of scientists and clinicians with expertise in drug discovery, the company focuses on creating novel antibodies for conditions such as pulmonary arterial hypertension and tumor angiogenesis, aiming to translate mechanistic insights into clinical candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Therapeutic options for pulmonary arterial hypertension (PAH) and tumor angiogenesis are limited, and existing treatments often lack specificity, leading to suboptimal efficacy and side effects. Developing novel biologics that precisely target vascular pathways is a complex, resource‑intensive process that many companies struggle to execute efficiently.
Solution
Interact Bio applies its combined expertise in vascular biology and antibody engineering to discover and develop therapeutic antibodies for PAH, tumor angiogenesis, and related vascular diseases. The company utilizes mechanistic insights from clinical and preclinical research to identify disease‑relevant targets, then leverages proprietary antibody discovery platforms to generate high‑affinity candidates. These candidates are advanced through in‑vitro and in‑vivo preclinical studies, with a focus on optimizing pharmacology, safety, and manufacturability. By integrating deep domain knowledge with a proven drug‑development pipeline, Interact Bio aims to translate mechanistically driven concepts into viable therapeutic programs for unmet medical needs.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking partner programs or licensing opportunities for vascular‑targeted antibody therapeutics, as well as research institutions pursuing collaborative preclinical development.
Features
- Targeted antibody discovery pipeline focused on vascular biology pathways implicated in PAH and tumor angiogenesis
- Integration of clinical insights from experienced physicians with cutting‑edge molecular engineering techniques
- In‑depth preclinical validation including functional assays, disease models, and safety profiling
- Proprietary platform for antibody optimization of affinity, specificity, and developability
- Mechanism‑of‑action driven candidate selection to enhance therapeutic relevance and reduce development risk